Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-768-7 | CAS number: 1663-39-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Aug 2002 - 04 Dec 2003 (experimental)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Aug 2002 - 04 Dec 2003 (experimental)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Version / remarks:
- May 12, 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- March 22, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental)
- Version / remarks:
- 712-C-00-368; July, 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Version / remarks:
- 712-C-98-204; August, 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EEC L133 (Sub-Chronic Inhalation Toxicity Study)
- Version / remarks:
- May 30, 1988
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Tert.- Butylacrylat
- Physical state: colorless liquid
- Analytical purity: 99.62% (Batch No. 2-011002-15/1) - 99.8% (Batch No. B602)
- Purity test report: Analytical report 02L00206 (Batch No. B602); reanalysis (Batch No. 2-011002-15/1)
- Stability under test conditions: The stability under storage conditions over the exposure period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage condition of test material: refrigerator, protected from light and stored under air - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: ca. 4 weeks
- Weight at study initiation: Males: 106.1-108.3 g; Females: 92.7-94.7 g (groupwise)
- Housing: individually in type DK II stainless steel wire mesh cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Underneath the DK III cages, waste trays were fixed containing bedding material (type 3/4 dust free embedding (SSNIFF, Soest, FRG)
- Diet: ad libitum, "GLP" (Provimi Kliba SA, Kaiseraugst, CH)
- Water: ad libitum, tap water
- Acclimation period: ca. 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- clean air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Piston metering pumps (Sarstedt DESAGA) and glass vaporizers with thermostat (BASF AG)
- Method of holding animals in test chamber: The animals were kept singly in wire cages located in a glass-steel inhalation chamber, volume of 1.4 m3 (BASF AG).
- Method of conditioning air: For each concentration the test substance was supplied to a thermostated vaporizer at a constant rate by means of the metering pump. The vapor was generated with conditioned supply air (about 50% ± 20% relative humidity, 22°C ± 2°C) and passed into the inhalation system.
- Temperature, pressure in air chamber: 25 ± 3°C, -10 Pa
- Air flow rate: 27.5-28.5 m3/h
TEST ATMOSPHERE
- Brief description of analytical method used: The concentrations of the inhalation atmospheres were analyzed by gas chromatography in all test groups including control (Hewlett-Packard 5840 A). Daily means were calculated based on 2 measured samples per concentration and exposure. From the daily mean values of each concentration, mean concentrations and standard deviations for the entire study were derived. The concentration constancy in each inhalation system was continuously monitored by means of a total hydrocarbon analyzer.
To ensure, that no liquid aerosols were formed at concentration levels as high as 180 ppm, a scattered light photometer was used to monitor the test atmosphere of the high dose group.
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Target concentrations were: 0.106, 0.319, and 0.956 mg/L (corresponding to 20, 60, and 180 ppm)
- Measured concentrations were: 0.107 ± 0.0061, 0.317 ± 0.0211, 0.958 ± 0.0481 mg/L - Duration of treatment / exposure:
- - males: 13 weeks (10 weeks premating, 3 weeks mating and post mating)
- females: ca. 15 weeks (10 weeks premating, during mating and gestation through day 4 after delivery) - Frequency of treatment:
- 6 hours/day, 5 days/week
- Dose / conc.:
- 0.106 mg/L air (nominal)
- Remarks:
- equals 20 ppm
- Dose / conc.:
- 0.319 mg/L air (nominal)
- Remarks:
- equals 60 ppm
- Dose / conc.:
- 0.956 mg/L air (nominal)
- Remarks:
- equals 180 ppm
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
106 mg/m3 (ca. 20 ppm) : as the expected no observed adverse effect level
319 mg/m3 (ca. 60 ppm) : as the intermediate dose level
956 mg/m3 (ca. 180 ppm): as the dose level where toxic effects were expected
Preflow period of 4 days - Positive control:
- none
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS:
- Time schedule: twice a day (in the morning and in the late afternoon) from Mondays to Fridays and once a day (in the morning) on Saturdays, Sundays and public holidays.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: at least 3 times (before, during and after exposure) on exposure days and once during the preflow period, on the day of neurofunctional test and prior to gross necropsy. During exposure only a group wise examination was possible. The nesting, littering, and lactation behavior of the dams was generally evaluated in the mornings in connection with the daily clinical inspection of the dams. The littering behavior of the dams was also inspected on each workday in the afternoons in addition to the evaluations in the mornings.
BODY WEIGHT:
- Time schedule for examinations: day -7, on day -4 (start preflow period), on day 0(start exposure period) and then in weekly intervals as well as prior to gross necropsy.
FOOD CONSUMPTION:
- Time schedule: day -7, on day -4 (start preflow period), on day 0 (start of exposure period) and then in weekly intervals.
- It was calculated as mean food consumption in grams per animal and day.
- Food efficiency (group means) was calculated based upon individual values for body weight and food consumption.
HAEMATOLOGY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: leukocytes, erythrocytes, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular, haemoglobin concentration, platelets, differential blood count, prothrombin time
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum-y-glutamyltransferase, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium, bile acids
URINALYSIS:
- Time schedule for collection of urine: not reported
- Analysis only performed in males
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Following parameters were examined: volume, colour, turbidity, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sediment
NEUROBEHAVIOURAL EXAMINATION:
- Detailed clinical observation (DCO) were performed in all animals prior to the exposure period and thereafter in weekly intervals. The findings were ranked according to the degree of severity, if applicable. The following parameters were examined: abnormal behaviour during handling, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, impairment of gait, lacrimation, palpebral closure, exophthalmus, faeces (appearance/consistency), urine, pupil size
- A functional observational battery (FOB) was carried out on the assigned animals (5 males and 5 females/ test group) on study days 56 and 57 for males and females, respectively. On the days of neurofunctional tests there was no exposure of the concerning animals as well as the other 5 animals of the same test group. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests. During the home cage observations attention was paid to posture, tremor, convulsions, abnormal movements, impairments of gait and other findings. During the open field observations the following parameters were examined: behaviour when removed from cage, fur, skin, salivation, nose discharge, lacrimation, eyes/pupil size, posture, palpebral closure, respiration, tremors, convulsions, abnormal movements, impairment of gait, activity/arousal level, faeces (number of faecal pellets/appearance/consistency) within two minutes, urine (appearance/quantity) within two minutes, number of rearings within 2 minutes and other findings. After the open field test animals were subjected to the following sensorimotor or reflex tests: approach response, touch response, vision (visual placing response), pupillary reflex, pinna reflex, audition (startle response), coordination of movements (righting response), behaviour during “handling”, vocalization, pain perception (tail pinch), grip strength of forelimbs, grip strength of hindlimbs, landing foot-splay test and other finding. All findings were ranked according to the degree of severity, if applicable. The observations were performed at random.
- Motor activity (MA) was measured on the same day and with the same animals as FOB was performed. The measurement was performed in the dark using the Multi-Varimex-System (Columbus Instruments Int. Corp., Ohio, USA) with 4 infrared beams per cage. During the measurement the animals were kept in Polycarbonate cages with absorbent material. The animals were put into the cages in a randomized order . The measurements started at about 14:00 p.m. The numbers of beam interrupts were counted over 12 intervals, each lasting 5 minutes. Measurement did not commence at the same instant for all cages ; the period of assessment for each animal started when the first beam was interrupted by pushing the cage into the rack (staggered start). Measurements ended exactly 60 minutes thereafter. During the measurements the animals received no food and no water. - Sacrifice and pathology:
- GROSS PATHOLOGY:
The animals were sacrificed under narcoren® anesthesia by exsanguination from the abdominal aorta and vena cava. The animals were necropsied and assessed by gross pathology. To prevent post mortem autolysis, the animals that died intercurrently were necropsied as soon as possible after death.
ORGAN WEIGHTS:
The following weights parameters from all animals sacrificed were determined: anesthetized animals, liver, kidneys, adrenal glands, testes, epididymides, uterus, thymus, spleen, brain, heart, lungs
HISTOPATHOLOGY:
-The following organs or tissues were fixed in 4% formaldehyde solution: all gross lesions, brain, spinal cord (cervical, thoracic and lumber cord), sciatic nerve, pituitary gland, salivary glands (glandula mandibularis and glandula sublingualis), thyroid glands/parathyroid glands, adrenal glands, prostate gland, seminal vesicles, coagulation glands, uterus, oviducts, vagina, female mammary gland, thymus, lymph nodes (mandibular and mesenteric), spleen, trachea, lungs, heart, aorta, liver, pancreas, kidneys, oesophagus, stomach (forestomach and glandular stomach), duodenum, jejunum ileum, caecum, colon, rectum, urinary bladder, sternum with marrow, bone marrow (femur), skull (with nasal cavities, larynx, pharynx, eyes with optic nerve, femur with knee joint, skin, skeletal muscle, extraorbital lacrimal glands. Testes, epididymides and ovaries of animals that were killed as scheduled were fixed in Bouin's solution and embedded in paraplast, thereafter . Testes, epididymides and ovaries of animals that died intercurrently were fixed in 4% formaldehyde solution.
- After the organs were fixed, histotechinical processing and examination was were performed as follows: Nasal cavities (level I- IV), Larynx (level I- III), Trachea (longitudinal, with carina), Lungs (5 lobes) and thyroid glands/parathyroid glands in all animals; all gross lesions in all affected animals; evaluations of all other organs and tissues fixed were only performed in animals of the control and high dose group - Statistics:
- Two-sided Dunnett test for food consumption, body weight and body weight change, number of mating days, duration of gestation, number of pups delivered per litter. Pairwise comparison by the Fisher´s exact test for male and female mating index, male and female fertility index, gestation index, females with liveborn pups, females with stillborn pups, females with all stillborn pups, live birth index, pups stillborn, pups died, pups cannibalized, pups sacrificed moribund, viability index, lactation index, number of litters with affected pups at necropsy and urine analysis except volume, colour, turbidity and specific gravity. Pairwise comparison by the Wilcoxon test for the proportions of affected pups per litter with necropsy observations. Non-parametric Kruskal-Wallis test (two-sided)/Wilcoxon test for feces, rearing, grip strength forelimbs, grip strength hindlimbs, landing foot-splay test, motor activity for the different time intervals, clinical pathology parameters except differential blood count and organ weights.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- During the study period one male animal of the control group showed injuries laterally at right flank and on the right head. This injury was of mechanic matter and was therefore not related to the study. One female animal of the low concentration group showed alopecia on dorsal body region and on both forelimbs. This was most likely to be incidental, because alopecia was not observed in other animals of the low and mid concentration group. At the high concentration (0.956 mg/L) male and female animals showed various clinical abnormalities comprising slight to moderate visually increased respiration, eyelid closure, salivation, eye discharge (red) indicating that the test substance was irritating to eyes and upper respiratory tract at this high concentration. Other findings like aggressiveness, apathy (1 female), as well as alopecia and piloerection were more of general nature indicating the bad general state of the animals.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Unspecific clinical symptoms indicative for some irritation and systemic toxicity (comprising visually increased respiration, salivation, piloerection, eyelid closure, eye discharge, alopecia, aggressiveness, hyperactivity and apathy) - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Two female animals exposed to the high concentration died on study day 88 and 91 (day 18 and 20 of gestation), respectively. Both animals were found pregnant at death.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight development of the high concentration animals was substantially impaired by the exposure to the test substance. Although the mean body weights on some examination days were not of statistical significance, the significantly reduced mean body weight gains proved the existence of this effect. The retardation of the body weight development is not only of secondary matter due to the reduced food consumption.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Test group 3 (0.956 mg/l = 180 ppm):
Retarded body weight development of the males
- mean body weight: - 8.1 % to - 15.5 % of the control from study day 9 onward (statistically significant to a level of 99 %)
- mean body weight gain: -23.2 % to -36.3 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Retarded body weight development of the females
- mean body weight: - 3.0 % to - 8.0 % of the control from study day 9 onward (statistically significant on study day 51 to a level of 95 %)
- mean body weight gain: -19.9 % to - 41.8 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Significantly (to a level of 99 %) decreased mean terminal body weight in males and in females (- 17.2 % and -9.4 %, resp.) - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The food consumption of the high concentration animals was either decreased only marginally and of transient matter, or increased slightly compared to the control.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- The food efficiency of the high concentration animals was, when compared with the control, only reduced transiently at the beginning of the exposure (day 9).
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There are no treatment-related changes in the haematological parameters measured. Clotting analysis revealed prolonged prothrombin times in the blood of the males of the high concentration group at the end of the study.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Regarding clinical pathology findings, in the high concentration group females, indications of a reduced general state was seen, characterized by significantly decreased serum creatinine, total protein, albumin and globulin levels. No treatment-related effects were observed in the clinical pathology parameters of the animals of the low and mid concentration groups.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm): :
-Increased prothrombin times, urea*, magnesium*, urinary specific gravity and urinary casts* in the males
-Decreased triglycerides** and urinary volume in the males
-Decreased chloride, creatinine*, total bilirubin, total protein**, albumin* and globulins** in the females
(* statistically significant to a level of 95 %
** statistically significant to a level of 99 %) - Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Regarding clinical pathology findings, treatment-related effects were observed only in the high concentration groups. The investigations revealed mild impairment of renal function in the males, substantiated by slightly increased urea concentrations in the serum, excretion of decreased urinary volume with increased specific gravity and the presence of urinary casts.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No treatment related findings were observed in the functional observation battery and motor activity examinations.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The administration of the test article had significantly decreased the mean terminal body weight of male and female rats of the high dose group. As a consequence of the treatment-related body weight loss, a few absolute organ weights were significantly decreased in males of the high dose group (liver and thymus), while the mean relative weights were significantly increased in males (lungs, kidneys, testes, epididymides, brain and adrenal glands) and in females (kidneys and brain) of the high dose group. No morphologic alterations were noted in the organs with significant weight changes that may account for them. Therefore, these organ weight changes were regarded not to be treatment-related per se but to be the consequence of the significantly decreased mean terminal body weight.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Two female animals of the high dose group died prematurely, revealing non-specific organ changes (atrophy) in the lymphoid tissues of spleen and thymus (both animals) or prefinal erosion/ulcer in the mucosa of the glandular stomach (one animal). Although these findings rather reflect the consequence of a longer story of illness than a treatment-related effect and although none of the findings in thymus, spleen and/or glandular stomach were recorded in the animals killed at scheduled dates, a relationship of the premature death of both animals to the administration of the test article could not be excluded.
Most of the gross lesions recorded were either single observations, or they occurred in control animals only, or they were recorded at low or at comparable incidence in control and high dose males and/or females. Hence, they were all regarded to have developed by chance and unrelated to treatment. - Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Histopathology detected treatment-related hyperplasia of the respiratory epithelium in the anterior part of the nasal cavity (cut level I) of males (higher incidence) and of females (higher grades of severity). One male of the high dose group showed hyperplasia of the respiratory epithelium also in cut level III of the nasal cavity.
Hyperplasia of the respiratory epithelium in the nasal cavity was interpreted as an adaptive, reversible reaction to the inhaled test article.
All other microscopic findings recorded were either single observations, or they occurred in control animals only, or they were recorded at low or at comparable incidence and graded severity in control and high dose males and/or females. Hence, they were all regarded to have developed fortuitously and unrelated to treatment.
Summary of the treatment-related findings, test group 3 (0.956 mg/l = 180 ppm):
Hyperplasia of the respiratory epithelium in the nasal cavity at level I in male (incidence) and in female rats (graded severity, only)
Hyperplasia of the respiratory epithelium in the nasal cavity at level III in one male rat. - Histopathological findings: neoplastic:
- not examined
- Details on results:
- Summary of the treatment-related findings:
Test group 2 (0.319 mg/L = 60 ppm): no treatment-related findings
Test group 1 (0.106 mg/L = 20 ppm): no treatment-related findings - Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- histopathology: non-neoplastic
- mortality
- urinalysis
- Key result
- Critical effects observed:
- no
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Aug 2002 - 04 Dec 2003 (experimental)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD guideline 413 (Sub-Chronic Inhalation Toxicity: 90-day Study)
- Version / remarks:
- May 12, 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- March 22, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental)
- Version / remarks:
- 712-C-00-368; July, 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Version / remarks:
- 712-C-98-204; August, 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EEC L133 (Sub-Chronic Inhalation Toxicity Study)
- Version / remarks:
- May 30, 1988
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Tert.- Butylacrylat
- Physical state: colorless liquid
- Analytical purity: 99.62% (Batch No. 2-011002-15/1) - 99.8% (Batch No. B602)
- Purity test report: Analytical report 02L00206 (Batch No. B602); reanalysis (Batch No. 2-011002-15/1)
- Stability under test conditions: The stability under storage conditions over the exposure period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage condition of test material: refrigerator, protected from light and stored under air - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: ca. 4 weeks
- Weight at study initiation: Males: 106.1-108.3 g; Females: 92.7-94.7 g (groupwise)
- Housing: individually in type DK II stainless steel wire mesh cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Underneath the DK III cages, waste trays were fixed containing bedding material (type 3/4 dust free embedding (SSNIFF, Soest, FRG); from day 18 post coitum until sacrifice, the pregnant animals and their litters were housed in Markolon M III cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Pregnant females were provided with nesting material (cellulose wadding) towards the end of pregnancy.
- Diet: ad libitum, "GLP" (Provimi Kliba SA, Kaiseraugst, CH)
- Water: ad libitum, tap water
- Acclimation period: ca. 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: clean air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Piston metering pumps (Sarstedt DESAGA) and glass vaporizers with thermostat (BASF AG)
- Method of holding animals in test chamber: The animals were kept singly in wire cages located in a glass-steel inhalation chamber, volume of 1.4 m3 (BASF AG).
- Method of conditioning air: For each concentration the test substance was supplied to a thermostated vaporizer at a constant rate by means of the metering pump. The vapor was generated with conditioned supply air (about 50% ± 20% relative humidity, 22°C ± 2°C) and passed into the inhalation system.
- Temperature, pressure in air chamber: 25 ± 3°C, -10 Pa
- Air flow rate: 27.5-28.5 m3/h
TEST ATMOSPHERE
- Brief description of analytical method used: The concentrations of the inhalation atmospheres were analyzed by gas chromatography in all test groups including control (Hewlett-Packard 5840 A). Daily means were calculated based on 2 measured samples per concentration and exposure. From the daily mean values of each concentration, mean concentrations and standard deviations for the entire study were derived. The concentration constancy in each inhalation system was continuously monitored by means of a total hydrocarbon analyzer.
To ensure, that no liquid aerosols were formed at concentration levels as high as 180 ppm, a scattered light photometer was used to monitor the test atmosphere of the high dose group.
- Samples taken from breathing zone: yes - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: from study day 69 - study day 80
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Target concentrations were: 0.106, 0.319, and 0.956 mg/L (corresponding to 20, 60, and 180 ppm)
- Measured concentrations were: 0.107 ± 0.0061, 0.317 ± 0.0211, 0.958 ± 0.0481 mg/L - Duration of treatment / exposure:
- - males: ca. 13 weeks (10 weeks premating, 3 weeks mating and post mating)
- females: ca. 15 weeks (10 weeks premating, during mating and gestation through day 4 after delivery) - Frequency of treatment:
- 6 hours/day, 5 days/week
- Details on study schedule:
- - Age at mating of the mated animals in the study: 16 weeks
- After ten weeks of exposure, the parental animals were mated to produce a litter. Mating pairs were formed from the same concentration group. The parental animals were examined for their mating and reproductive performances.
- The pups were sexed and were weighed on the day after birth and on day 4 post partum. Their viability was recorded. All pups were necropsied on day 4 post partum and were examined macroscopically for external and visceral findings. - Dose / conc.:
- 0.106 mg/L air (nominal)
- Remarks:
- equals 20 ppm
- Dose / conc.:
- 0.319 mg/L air (nominal)
- Remarks:
- equals 60 ppm
- Dose / conc.:
- 0.956 mg/L air (nominal)
- Remarks:
- equals 180 ppm
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
0.106 mg/L (ca. 20 ppm) : as the expected no observed adverse effect level
0.319 mg/L (ca. 60 ppm) : as the intermediate dose level
0.956 mg/L (ca. 180 ppm): as the dose level where toxic effects were expected
Preflow period of 4 days - Positive control:
- none
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS:
- Time schedule: twice a day (in the morning and in the late afternoon) from Mondays to Fridays and once a day (in the morning) on Saturdays, Sundays and public holidays.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: at least 3 times (before, during and after exposure) on exposure days and once during the preflow period, on the day of neurofunctional test and prior to gross necropsy. During exposure only a group wise examination was possible. The nesting, littering, and lactation behavior of the dams was generally evaluated in the mornings in connection with the daily clinical inspection of the dams. The littering behavior of the dams was also inspected on each workday in the afternoons in addition to the evaluations in the mornings.
BODY WEIGHT:
- Time schedule for examinations: day -7, on day -4 (start preflow period), on day 0(start exposure period) and then in weekly intervals as well as prior to gross necropsy.
FOOD CONSUMPTION:
- Time schedule: day -7, on day -4 (start preflow period), on day 0 (start of exposure period) and then in weekly intervals.
- It was calculated as mean food consumption in grams per animal and day.
- Food efficiency (group means) was calculated based upon individual values for body weight and food consumption.
HAEMATOLOGY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: leukocytes, erythrocytes, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular, haemoglobin concentration, platelets, differential blood count, prothrombin time
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum-y-glutamyltransferase, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium, bile acids
URINALYSIS:
- Time schedule for collection of urine: not reported
- Analysis only performed in males
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Following parameters were examined: volume, colour, turbidity, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sediment
NEUROBEHAVIOURAL EXAMINATION:
- Detailed clinical observation (DCO) were performed in all animals prior to the exposure period and thereafter in weekly intervals. The findings were ranked according to the degree of severity, if applicable. The following parameters were examined: abnormal behaviour during handling, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, impairment of gait, lacrimation, palpebral closure, exophthalmus, faeces (appearance/consistency), urine, pupil size
- A functional observational battery (FOB) was carried out on the assigned animals (5 males and 5 females/ test group) on study days 56 and 57 for males and females, respectively. On the days of neurofunctional tests there was no exposure of the concerning animals as well as the other 5 animals of the same test group. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests. During the home cage observations attention was paid to posture, tremor, convulsions, abnormal movements, impairments of gait and other findings. During the open field observations the following parameters were examined: behaviour when removed from cage, fur, skin, salivation, nose discharge, lacrimation, eyes/pupil size, posture, palpebral closure, respiration, tremors, convulsions, abnormal movements, impairment of gait, activity/arousal level, faeces (number of faecal pellets/appearance/consistency) within two minutes, urine (appearance/quantity) within two minutes, number of rearings within 2 minutes and other findings. After the open field test animals were subjected to the following sensorimotor or reflex tests: approach response, touch response, vision (visual placing response), pupillary reflex, pinna reflex, audition (startle response), coordination of movements (righting response), behaviour during “handling”, vocalization, pain perception (tail pinch), grip strength of forelimbs, grip strength of hindlimbs, landing foot-splay test and other finding. All findings were ranked according to the degree of severity, if applicable. The observations were performed at random.
- Motor activity (MA) was measured on the same day and with the same animals as FOB was performed. The measurement was performed in the dark using the Multi-Varimex-System (Columbus Instruments Int. Corp., Ohio, USA) with 4 infrared beams per cage. During the measurement the animals were kept in Polycarbonate cages with absorbent material. The animals were put into the cages in a randomized order . The measurements started at about 14:00 p.m. The numbers of beam interrupts were counted over 12 intervals, each lasting 5 minutes. Measurement did not commence at the same instant for all cages ; the period of assessment for each animal started when the first beam was interrupted by pushing the cage into the rack (staggered start). Measurements ended exactly 60 minutes thereafter. During the measurements the animals received no food and no water. - Oestrous cyclicity (parental animals):
- not reported
- Sperm parameters (parental animals):
- not reported
- Litter observations:
- PARAMETERS EXAMINED:
The following parameters were examined in F1 offspring: number and sex of pups, weight gain (The pups were weighed on the day after birth (day 1 p.p.) and on day 4 after birth), stillbirths, live births, postnatal mortality, presence of gross anomalies
GROSS EXAMINATION OF DEAD PUPS:
yes, for abnormalities. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals 3 weeks after mating
- Maternal animals: All surviving animals after d4 of gestation
GROSS PATHOLOGY:
The animals were sacrificed under narcoren® anesthesia by exsanguination from the abdominal aorta and vena cava. The animals were necropsied and assessed by gross pathology. To prevent post mortem autolysis, the animals that died intercurrently were necropsied as soon as possible after death.
ORGAN WEIGHTS:
The following weights parameters from all animals sacrificed were determined: anesthetized animals, liver, kidneys, adrenal glands, testes, epididymides, uterus, thymus, spleen, brain, heart, lungs
HISTOPATHOLOGY:
-The following organs or tissues were fixed in 4% formaldehyde solution: all gross lesions, brain, spinal cord (cervical, thoracic and lumber cord), sciatic nerve, pituitary gland, salivary glands (glandula mandibularis and glandula sublingualis), thyroid glands/parathyroid glands, adrenal glands, prostate gland, seminal vesicles, coagulation glands, uterus, oviducts, vagina, female mammary gland, thymus, lymph nodes (mandibular and mesenteric), spleen, trachea, lungs, heart, aorta, liver, pancreas, kidneys, oesophagus, stomach (forestomach and glandular stomach), duodenum, jejunum ileum, caecum, colon, rectum, urinary bladder, sternum with marrow, bone marrow (femur), skull (with nasal cavities, larynx, pharynx, eyes with optic nerve, femur with knee joint, skin, skeletal muscle, extraorbital lacrimal glands. Testes, epididymides and ovaries of animals that were killed as scheduled were fixed in Bouin's solution and embedded in paraplast, thereafter . Testes, epididymides and ovaries of animals that died intercurrently were fixed in 4% formaldehyde solution.
- After the organs were fixed, histotechinical processing and examination was were performed as follows: Nasal cavities (level I- IV), Larynx (level I- III), Trachea (longitudinal, with carina), Lungs (5 lobes) and thyroid glands/parathyroid glands in all animals; all gross lesions in all affected animals; evaluations of all other organs and tissues fixed were only performed in animals of the control and high dose group - Postmortem examinations (offspring):
- GROSS NECROPSY
All surviving pups (after sacrifice on day 4 p .p . by means of C02), all stillborn pups and those pups that died before schedule, were examined externally, eviscerated and their organs were assessed macroscopically.
All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation. - Statistics:
- Two-sided Dunnett test for food consumption, body weight and body weight change, number of mating days, duration of gestation, number of pups
delivered per litter.
Pairwise comparison by the Fisher´s exact test for male and female mating index, male and female fertility index, gestation index, females with liveborn pups, females with stillborn pups, females with all stillborn pups, live birth index, pups stillborn, pups died, pups cannibalized, pups sacrificed moribund, viability index, lactation index, number of litters with affected pups at necropsy and urine analysis except vlume, color, turbidity and specific gravity.
Pairwise comparison by the Wilcoxon test for the proportions of affected pups per litter with necropsy observations.
Non-parametric Kruskal-Wallis test (two-sided)/Wilcoxon test for feces, rearing, grip strength forelimbs, grip strength hindlimbs, landing foot-splay test, motor activity for the different time intervals, clinical pathology parameters except differential blood count and organ weights. - Reproductive indices:
- - Male mating index (%) = number of males with confirmed mating / number of males places with females x 100
- Male fertility index (%) = number of males proving their fertility / number of males place with females x 100
- Female mating index (%) = number of females mated / number of females placed with males x 100
- Female fertility index (%) = number of females pregnant / number of females mated x 100
- Gestation index (%) = number of females with live pups on the day of birth / number of females pregnant x 100 - Offspring viability indices:
- - Viability index (%) = number of live pups on day 4 after birth / number of liveborn pups on the day of birth x 100
- Sex ratio (%) – number of live male or female pups on day (0/4) / number of live male and female pups on day (0/4) x 100 - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- During the study period one male animal of the control group showed injuries laterally at right flank and on the right head. This injury was of mechanic matter and was therefore not related to the study. One female animal of the low concentration group showed alopecia on dorsal body region and on both forelimbs. This was most likely to be incidental, because alopecia was not observed in other animals of the low and mid concentration group. At the high concentration (0.956 mg/L) male and female animals showed various clinical abnormalities comprising slight to moderate visually increased respiration, eyelid closure, salivation, eye discharge (red) indicating that the test substance was irritating to eyes and upper respiratory tract at this high concentration. Other findings like aggressiveness, apathy (1 female), as well as alopecia and piloerection were more of general nature indicating the bad general state of the animals.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Unspecific clinical symptoms indicative for some irritation and systemic toxicity (comprising visually increased respiration, salivation, piloerection, eyelid closure, eye discharge, alopecia, aggressiveness, hyperactivity and apathy) - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Two female animals exposed to the high concentration died on study day 88 and 91 (day 18 and 20 of gestation), respectively. Both animals were found pregnant at death.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight development of the high concentration animals was substantially impaired by the exposure to the test substance. Although the mean body weights on some examination days were not of statistical significance, the significantly reduced mean body weight gains proved the existence of this effect. The retardation of the body weight development is not only of secondary matter due to the reduced food consumption.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Test group 3 (0.956 mg/l = 180 ppm):
Retarded body weight development of the males
- mean body weight: - 8.1 % to - 15.5 % of the control from study day 9 onward (statistically significant to a level of 99 %)
- mean body weight gain: -23.2 % to - 36.3 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Retarded body weight development of the females
- mean body weight: - 3.0 % to -8.0 % of the control from study day 9 onward (statistically significant on study day 51 to a level of 95 %)
- mean body weight gain: -19.9 % to - 41.8 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Significantly (to a level of 99 %) decreased mean terminal body weight in males and in females (- 17.2 % and -9.4 %, resp.)
Reduced body weight development in the dams during pregnancy and lactation
- Average weight gain 61 % less than the control between days 0-20 of pregnancy
- Mean body weight on day 20 of pregnancy 24% below control
- Body weights persisted being 19-23% below control during lactation days 0-4, though weight gain was about 60% above control in these females after cessation of exposure on gestation day 18 - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The food consumption of the high concentration animals was either decreased only marginally and of transient matter, or increased slightly compared to the control.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- The food efficiency of the high concentration animals was, when compared with the control, only reduced transiently at the beginning of the exposure (day 9).
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There are no treatment-related changes in the haematological parameters measured. Clotting analysis revealed prolonged prothrombin times in the blood of the males of the high concentration group at the end of the study.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Regarding clinical pathology findings, in the high concentration group females, indications of a reduced general state was seen, characterized by significantly decreased serum creatinine, total protein, albumin and globulin levels. No treatment-related effects were observed in the clinical pathology parameters of the animals of the low and mid concentration groups.
Summary of the treatment-related findings, test group 3 (0.956 mg/l = 180 ppm): :
-Increased prothrombin times, urea*, magnesium*, urinary specific gravity and urinary casts* in the males
-Decreased triglycerides** and urinary volume in the males
-Decreased chloride, creatinine*, total bilirubin, total protein**, albumin* and globulins** in the females
(* statistically significant to a level of 95 %
** statistically significant to a level of 99 %) - Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Regarding clinical pathology findings, treatment-related effects were observed only in the high concentration groups. The investigations revealed mild impairment of renal function in the males, substantiated by slightly increased urea concentrations in the serum, excretion of decreased urinary volume with increased specific gravity and the presence of urinary casts.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No treatment related findings were observed in the functional observation battery and motor activity examinations.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Histopathology detected treatment-related hyperplasia of the respiratory epithelium in the anterior part of the nasal cavity (cut level I) of males (higher incidence) and of females (higher grades of severity). One male of the high dose group showed hyperplasia of the respiratory epithelium also in cut level III of the nasal cavity.
Hyperplasia of the respiratory epithelium in the nasal cavity was interpreted as an adaptive, reversible reaction to the inhaled test article.
All other microscopic findings recorded were either single observations, or they occurred in control animals only, or they were recorded at low or at comparable incidence and graded severity in control and high dose males and/or females. Hence, they were all regarded to have developed fortuitously and unrelated to treatment.
Summary of the treatment-related findings, test group 3 (0.956 mg/l = 180 ppm): :
Hyperplasia of the respiratory epithelium in the nasal cavity at level I in male (incidence) and in female rats (graded severity, only)
Hyperplasia of the respiratory epithelium in the nasal cavity at level III in one male rat. - Histopathological findings: neoplastic:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- - Male cohabitation data
For all F0 parental males, which were placed with females to generate F1 pups, mating was confirmed. Thus, the male mating index reached 100% in all groups, including the controls.
Fertility could be proven for nearly all F0 parental males within the scheduled mating interval for F1 litter. One mid dose male and one high dose male did not generate F1 pups. Thus, the male fertility index ranged between 89% and 100%. These values reflect the normal range of biological variation inherent in the strain of rats used for this study. For none of the affected male rats conclusive histopathological findings were gathered which could account for the observed impaired fertility.
- Female reproduction and delivery data
The female mating index calculated after the mating period for F1 litter was 100% for all groups.
The mean cohabitation time (duration until sperm was detected (i.e. day 0 p.c.)) amounted to 3.3 days/2.3 days/2.5 days/2.0 days (0, 0.106, 0.319 and 0.956 mg/l). These values reflect the normal range of biological variation inherent in the strain used in this study. Consequently, the differences between the groups are assessed as spontaneous in nature and without any biological relevance.
All sperm positive rats delivered pups with the following exceptions: one mid dose F0 parental female and one high dose female did not become pregnant. Therefore, the fertility indices ranged between 89% and 100%.
The mean duration of gestation was very similar in the test groups 0-3 (between 21.8 and 21.9 days).
The gestation index was 100% in test groups exposed to 0, 0.106 and 0.319 mg/l, but was markedly reduced to 67% in the high dose group (0.956 mg/L). Only 4 out of 6 surviving presumed pregnant females had liveborn pups in the high dose group.
The number of liveborn and stillborn pups was comparable between the control and test groups 1 and 2, while there were a statistically significantly decreased number of liveborn and an increased number of stillborn pups in test group 3. Thus, the live birth index amounted to 100% in test groups exposed to 0, 0.106 and 0.319 mg/l and 80% in test group 3 (0.956 mg/L). - Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- urinalysis
- histopathology: non-neoplastic
- Remarks on result:
- other: marked maternal toxicity, including mortality
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
- Key result
- Critical effects observed:
- no
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- Test group 3 (956 mg/m3 ): markedly lower viability index (20% vs 97% in the control)
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Test group 3 (956 mg/m3 ): lower pup body weights on day 1 p .p . (28% below control ). Average pup body weights and body weight gain significantly below control (42% on
day 4 p.p. and 67% for days 1-4 p.p., respectively) - Sexual maturation:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- mortality
- body weight and weight gain
- Key result
- Critical effects observed:
- no
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 0.956 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects as a secondary non-specific consequence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- yes
cohabitation time (days): 3.3 - 2.3 - 2.5 - 2.0
male mating index (%) : 100 - 100 - 100 - 100
male fertility index (%): 100 - 100 - 90 - 89
female mating index (%): 100 - 100 - 100 - 100
female fertility index (%) 100 100 90 89
duration of gestation (days) 21.8 21.9 21.9 21.8
gestation index (%) 100 100 100 67
pups delivered 11.0 9.7 10.4 8.3
live birth index (%) 100 100 100 80**
Stillborn (%) 0 0 0 20**
(** significant to a level of 99 %)
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- neurotoxicity: sub-chronic inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Aug 2002 - 04 Dec 2003 (experimental)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Version / remarks:
- May 12, 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- March 22, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental)
- Version / remarks:
- 712-C-00-368; July, 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Version / remarks:
- 712-C-98-204; August, 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EEC L133 (Sub-Chronic Inhalation Toxicity Study)
- Version / remarks:
- May 30, 1988
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Tert.- Butylacrylat
- Physical state: colorless liquid
- Analytical purity: 99.62% (Batch No. 2-011002-15/1) - 99.8% (Batch No. B602)
- Purity test report: Analytical report 02L00206 (Batch No. B602); reanalysis (Batch No. 2-011002-15/1)
- Stability under test conditions: The stability under storage conditions over the exposure period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage condition of test material: refrigerator, protected from light and stored under air - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: ca. 4 weeks
- Weight at study initiation: Males: 106.1-108.3 g; Females: 92.7-94.7 g (groupwise)
- Housing: individually in type DK II stainless steel wire mesh cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Underneath the DK III cages, waste trays were fixed containing bedding material (type 3/4 dust free embedding (SSNIFF, Soest, FRG)
- Diet: ad libitum, "GLP" (Provimi Kliba SA, Kaiseraugst, CH)
- Water: ad libitum, tap water
- Acclimation period: ca. 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Vehicle:
- other: clean air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Piston metering pumps (Sarstedt DESAGA) and glass vaporizers with thermostat (BASF AG)
- Method of holding animals in test chamber: The animals were kept singly in wire cages located in a glass-steel inhalation chamber, volume of 1.4 m3 (BASF AG).
- Method of conditioning air: For each concentration the test substance was supplied to a thermostated vaporizer at a constant rate by means of the metering pump. The vapor was generated with conditioned supply air (about 50% ± 20% relative humidity, 22°C ± 2°C) and passed into the inhalation system.
- Temperature, pressure in air chamber: 25 ± 3°C, -10 Pa
- Air flow rate: 27.5-28.5 m3/h
TEST ATMOSPHERE
- Brief description of analytical method used: The concentrations of the inhalation atmospheres were analyzed by gas chromatography in all test groups including control (Hewlett-Packard 5840 A). Daily means were calculated based on 2 measured samples per concentration and exposure. From the daily mean values of each concentration, mean concentrations and standard deviations for the entire study were derived. The concentration constancy in each inhalation system was continuously monitored by means of a total hydrocarbon analyzer.
To ensure, that no liquid aerosols were formed at concentration levels as high as 180 ppm, a scattered light photometer was used to monitor the test atmosphere of the high dose group.
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Target concentrations were: 0.106, 0.319, and 0.956 mg/L (corresponding to 20, 60, and 180 ppm)
- Measured concentrations were: 0.107 ± 0.0061, 0.317 ± 0.0211, 0.958 ± 0.0481 mg/L - Duration of treatment / exposure:
- - males: ca. 13 weeks (10 weeks premating, 3 weeks mating and post mating)
- females: ca. 15 weeks (10 weeks premating, during mating and gestation through day 4 after delivery) - Frequency of treatment:
- 6 hours/day, 5 days/week
- Dose / conc.:
- 0.106 mg/L air (nominal)
- Remarks:
- equals 20 ppm
- Dose / conc.:
- 0.319 mg/L air (nominal)
- Remarks:
- equals 60 ppm
- Dose / conc.:
- 0.956 mg/L air (nominal)
- Remarks:
- equals 120 ppm
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
0.106 mg/L (ca. 20 ppm) : as the expected no observed adverse effect level
0.319 mg/L (ca. 60 ppm) : as the intermediate dose level
0.956 mg/L (ca. 180 ppm): as the dose level where toxic effects were expected
Preflow period of 4 days - Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice a day (in the morning and in the late afternoon) from Mondays to Fridays and once a day (in the morning) on Saturdays, Sundays and public holidays
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least 3 times (before, during and after exposure) on exposure days and once during the preflow period, on the day of neurofunctional test and prior to gross necropsy. During exposure only a group wise examination was possible. The nesting, littering, and lactation behavior of the dams was generally evaluated in the mornings in connection with the daily clinical inspection of the dams.
The littering behavior of the dams was also inspected on each workday in the afternoons in
addition to the evaluations in the mornings.
BODY WEIGHT: Yes
- Time schedule for examinations: day -7, on day -4 (start preflow period), on day 0(start exposure period) and then in weekly intervals as well
as prior to gross necropsy.
CAGE SIDE OBSERVATIONS:
- Time schedule: twice a day (in the morning and in the late afternoon) from Mondays to Fridays and once a day (in the morning) on Saturdays, Sundays and public holidays.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: at least 3 times (before, during and after exposure) on exposure days and once during the preflow period, on the day of neurofunctional test and prior to gross necropsy. During exposure only a group wise examination was possible. The nesting, littering, and lactation behavior of the dams was generally evaluated in the mornings in connection with the daily clinical inspection of the dams. The littering behavior of the dams was also inspected on each workday in the afternoons in addition to the evaluations in the mornings.
BODY WEIGHT:
- Time schedule for examinations: day -7, on day -4 (start preflow period), on day 0(start exposure period) and then in weekly intervals as well as prior to gross necropsy.
FOOD CONSUMPTION:
- Time schedule: day -7, on day -4 (start preflow period), on day 0 (start of exposure period) and then in weekly intervals.
- It was calculated as mean food consumption in grams per animal and day.
- Food efficiency (group means) was calculated based upon individual values for body weight and food consumption.
HAEMATOLOGY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: leukocytes, erythrocytes, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular, haemoglobin concentration, platelets, differential blood count, prothrombin time
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum-y-glutamyltransferase, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium, bile acids
URINALYSIS:
- Time schedule for collection of urine: not reported
- Analysis only performed in males
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Following parameters were examined: volume, colour, turbidity, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sediment - Neurobehavioural examinations performed and frequency:
- NEUROBEHAVIOURAL EXAMINATION:
Detailed clinical observation (DCO) were performed in all animals prior to the exposure period and thereafter in weekly intervals. The findings were ranked according to the degree of severity, if applicable.
A functional observational battery (FOB) was carried out on the assigned animals (5 males and 5 females/ test group) on study days 56 and 57 for males and females, respectively. On the days of neurofunctional tests there was no exposure of the concerning animals as well as the other 5 animals of the same test group. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests. The findings were ranked according to the degree of severity, if applicable. The observations were performed at random.
Home cage observations:
The animals were observed in their closed home cages; any disturbing activities (touching the cage or rack, noise) were avoided during these examinations in order not to influence the behaviour of the animals. Attention was paid to:
1. posture
2. tremor
3. convulsions
4. abnormal movements
5. impairment of gait
6. other findings
Open field observations :
The animals were transferred to a standard arena (50 x 50 cm with sides of 25 cm high) and observed for at least 2 minutes. Following parameters were examined:
1. behavior when removed from cage
2. fur
3. skin
4. salivation
5. nose discharge
6. lacrimation
7. eyes/pupil size
8. posture
9. palpebral closure
10. respiration
11. tremors
12. convulsions
13. abnormal movements
14. impairment of gait
15. activity/arousal level
16. feces (number of fecal pellets/appearance/consistency) within two minutes
17. urine (appearance/quantity) within two minutes
18. number of rearings within two minutes
19. other findings
Sensorimotor Tests/Reflexes:
The animals were removed from the open field and subjected to following sensorimotor or reflex tests:
1. approach response
2. touch response
3. vision ("visual placing response")
4. pupillary reflex
5. pinna reflex
6. audition ("startle response" )
7. coordination of movements ("righting response")
8. behaviour during "handling "
9. vocalization
10. pain perception ("tail pinch")
11. grip strength of forelimbs
12. grip strength of hindlimbs
13. landing foot-splay test
14. other findings
Motor activity (MA) was measured on the same day and with the same animals as FOB was performed. The measurement was performed in the dark using the Multi-Varimex-System (Columbus Instruments Int. Corp., Ohio, USA) with 4 infrared beams per cage. The numbers of beam interrupts were counted over 12 intervals, each lasting 5 minutes. Measurement did not commence at the same instant for all cages; the period of assessment for each animal started when the first beam was interrupted by pushing the cage into the rack (staggered start). Measurements ended exactly 60 minutes thereafter. During the measurements the animals received no food and no water. - Sacrifice and (histo)pathology:
- GROSS PATHOLOGY:
The animals were sacrificed under narcoren® anesthesia by exsanguination from the abdominal aorta and vena cava. The animals were necropsied and assessed by gross pathology. To prevent post mortem autolysis, the animals that died intercurrently were necropsied as soon as possible after death.
ORGAN WEIGHTS:
The following weights parameters from all animals sacrificed were determined: anesthetized animals, liver, kidneys, adrenal glands, testes, epididymides, uterus, thymus, spleen, brain, heart, lungs
HISTOPATHOLOGY:
-The following organs or tissues were fixed in 4% formaldehyde solution: all gross lesions, brain, spinal cord (cervical, thoracic and lumber cord), sciatic nerve, pituitary gland, salivary glands (glandula mandibularis and glandula sublingualis), thyroid glands/parathyroid glands, adrenal glands, prostate gland, seminal vesicles, coagulation glands, uterus, oviducts, vagina, female mammary gland, thymus, lymph nodes (mandibular and mesenteric), spleen, trachea, lungs, heart, aorta, liver, pancreas, kidneys, oesophagus, stomach (forestomach and glandular stomach), duodenum, jejunum ileum, caecum, colon, rectum, urinary bladder, sternum with marrow, bone marrow (femur), skull (with nasal cavities, larynx, pharynx, eyes with optic nerve, femur with knee joint, skin, skeletal muscle, extraorbital lacrimal glands. Testes, epididymides and ovaries of animals that were killed as scheduled were fixed in Bouin's solution and embedded in paraplast, thereafter . Testes, epididymides and ovaries of animals that died intercurrently were fixed in 4% formaldehyde solution.
- After the organs were fixed, histotechinical processing and examination was were performed as follows: Nasal cavities (level I- IV), Larynx (level I- III), Trachea (longitudinal, with carina), Lungs (5 lobes) and thyroid glands/parathyroid glands in all animals; all gross lesions in all affected animals; evaluations of all other organs and tissues fixed were only performed in animals of the control and high dose group - Positive control:
- none
- Statistics:
- Two-sided Dunnett test for food consumption, body weight and body weight change, number of mating days, duration of gestation, number of pups
delivered per litter.
Pairwise comparison by the Fisher´s exact test for male and female mating index, male and female fertility index, gestation index, females with liveborn pups, females with stillborn pups, females with all stillborn pups, live birth index, pups stillborn, pups died, pups cannibalized, pups sacrificed moribund, viability index, lactation index, number of litters with affected pups at necropsy and urine analysis except volume, colour, turbidity and specific gravity.
Pairwise comparison by the Wilcoxon test for the proportions of affected pups per litter with necropsy observations.
Non-parametric Kruskal-Wallis test (two-sided)/Wilcoxon test for feces, rearing, grip strength forelimbs, grip strength hindlimbs, landing foot-splay test, motor activity for the different time intervals, clinical pathology parameters except differential blood count and organ weights. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- During the study period one male animal of the control group showed injuries laterally at right flank and on the right head. This injury was of mechanic matter and was therefore not related to the study. One female animal of the low concentration group showed alopecia on dorsal body region and on both forelimbs. This was most likely to be incidental, because alopecia was not observed in other animals of the low and mid concentration group. At the high concentration (0.956 mg/L) male and female animals showed various clinical abnormalities comprising slight to moderate visually increased respiration, eyelid closure, salivation, eye discharge (red) indicating that the test substance was irritating to eyes and upper respiratory tract at this high concentration. Other findings like aggressiveness, apathy (1 female), as well as alopecia and piloerection were more of general nature indicating the bad general state of the animals.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Unspecific clinical symptoms indicative for some irritation and systemic toxicity (comprising visually increased respiration, salivation, piloerection, eyelid closure, eye discharge, alopecia, aggressiveness, hyperactivity and apathy) - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Two female animals exposed to the high concentration died on study day 88 and 91 (day 18 and 20 of gestation), respectively. Both animals were found pregnant at death.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight development of the high concentration animals was substantially impaired by the exposure to the test substance. Although the mean body weights on some examination days were not of statistical significance, the significantly reduced mean body weight gains proved the existence of this effect. The retardation of the body weight development is not only of secondary matter due to the reduced food consumption.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Test group 3 (0.956 mg/l = 180 ppm):
Retarded body weight development of the males
- mean body weight: - 8.1 % to - 15.5 % of the control from study day 9 onward (statistically significant to a level of 99 %)
- mean body weight gain: -23.2 % to -36.3 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Retarded body weight development of the females
- mean body weight: - 3.0 % to - 8.0 % of the control from study day 9 onward (statistically significant on study day 51 to a level of 95 %)
- mean body weight gain: -19.9 % to - 41.8 % of the control from study day 9 onward (statistically significant to a level of 99 %)
Significantly (to a level of 99 %) decreased mean terminal body weight in males and in females (- 17.2 % and -9.4 %, resp.) - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The food consumption of the high concentration animals was either decreased only marginally and of transient matter, or increased slightly compared to the control.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- The food efficiency of the high concentration animals was, when compared with the control, only reduced transiently at the beginning of the exposure (day 9).
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There are no treatment-related changes in the haematological parameters measured. Clotting analysis revealed prolonged prothrombin times in the blood of the males of the high concentration group at the end of the study.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No treatment related findings were observed in the functional observation battery and motor activity examinations.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The administration of the test article had significantly decreased the mean terminal body weight of male and female rats of the high dose group. As a consequence of the treatment-related body weight loss, a few absolute organ weights were significantly decreased in males of the high dose group (liver and thymus), while the mean relative weights were significantly increased in males (lungs, kidneys, testes, epididymides, brain and adrenal glands) and in females (kidneys and brain) of the high dose group. No morphologic alterations were noted in the organs with significant weight changes that may account for them. Therefore, these organ weight changes were regarded not to be treatment-related per se but to be the consequence of the significantly decreased mean terminal body weight.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Two female animals of the high dose group died prematurely, revealing non-specific organ changes (atrophy) in the lymphoid tissues of spleen and thymus (both animals) or prefinal erosion/ulcer in the mucosa of the glandular stomach (one animal). Although these findings rather reflect the consequence of a longer story of illness than a treatment-related effect and although none of the findings in thymus, spleen and/or glandular stomach were recorded in the animals killed at scheduled dates, a relationship of the premature death of both animals to the administration of the test article could not be excluded.
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Histopathology detected treatment-related hyperplasia of the respiratory epithelium in the anterior part of the nasal cavity (cut level I) of males (higher incidence) and of females (higher grades of severity). One male of the high dose group showed hyperplasia of the respiratory epithelium also in cut level III of the nasal cavity.
Hyperplasia of the respiratory epithelium in the nasal cavity was interpreted as an adaptive, reversible reaction to the inhaled test article.
All other microscopic findings recorded were either single observations, or they occurred in control animals only, or they were recorded at low or at comparable incidence and graded severity in control and high dose males and/or females. Hence, they were all regarded to have developed fortuitously and unrelated to treatment.
Summary of the treatment-related findings, test group 3 (0.956 mg/L = 180 ppm):
Hyperplasia of the respiratory epithelium in the nasal cavity at level I in male (incidence) and in female rats (graded severity, only)
Hyperplasia of the respiratory epithelium in the nasal cavity at level III in one male rat. - Histopathological findings: neoplastic:
- not examined
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- histopathology: non-neoplastic
- mortality
- urinalysis
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 0.956 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- Key result
- Critical effects observed:
- no
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- March 22, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Version / remarks:
- May 12, 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental)
- Version / remarks:
- 712-C-00-368; July, 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Version / remarks:
- 712-C-98-204; August, 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EEC L133 (Sub-Chronic Inhalation Toxicity Study)
- Version / remarks:
- May 30, 1988
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- tert-butyl acrylate
- EC Number:
- 216-768-7
- EC Name:
- tert-butyl acrylate
- Cas Number:
- 1663-39-4
- Molecular formula:
- C7H12O2
- IUPAC Name:
- tert-butyl acrylate
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Tert.- Butylacrylat
- Physical state: colorless liquid
- Analytical purity: 99.62% (Batch No. 2-011002-15/1) - 99.8% (Batch No. B602)
- Purity test report: Analytical report 02L00206 (Batch No. B602); reanalysis (Batch No. 2-011002-15/1)
- Stability under test conditions: The stability under storage conditions over the exposure period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage condition of test material: refrigerator, protected from light and stored under air
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: ca. 4 weeks
- Weight at study initiation: Males: 106.1-108.3 g; Females: 92.7-94.7 g (groupwise)
- Housing: individually in type DK II stainless steel wire mesh cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Underneath the DK III cages, waste trays were fixed containing bedding material (type 3/4 dust free embedding (SSNIFF, Soest, FRG); from day 18 post coitum until sacrifice, the pregnant animals and their litters were housed in Markolon M III cages (BECKER & CO., Castrop-Rauxel, Germany), floor area about 800 cm2. Pregnant females were provided with nesting material (cellulose wadding) towards the end of pregnancy.
- Diet: ad libitum, "GLP" (Provimi Kliba SA, Kaiseraugst, CH)
- Water: ad libitum, tap water
- Acclimation period: ca. 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: clean air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Piston metering pumps (Sarstedt DESAGA) and glass vaporizers with thermostat (BASF AG
- Method of holding animals in test chamber: The animals were kept singly in wire cages located in a glass-steel inhalation chamber, volume of 1.4 m3 (BASF AG).
- Method of conditioning air: For each concentration the test substance was supplied to a thermostated vaporizer at a constant rate by means of the metering pump. The vapor was generated with conditioned supply air (about 50% ± 20% relative humidity, 22°C ± 2°C) and passed into the inhalation system.
- Temperature, pressure in air chamber: 25 ± 3°C, -10 Pa
- Air flow rate: 27.5-28.5 m3/h
TEST ATMOSPHERE
- Brief description of analytical method used: The concentrations of the inhalation atmospheres were analyzed by gas chromatography in all test groups including control (Hewlett-Packard 5840 A). Daily means were calculated based on 2 measured samples per concentration and exposure. From the daily mean values of each concentration, mean concentrations and standard deviations for the entire study were derived. The concentration constancy in each inhalation system was continuously monitored by means of a total hydrocarbon analyzer.
To ensure, that no liquid aerosols were formed at concentration levels as high as 180 ppm, a scattered light photometer was used to monitor the test atmosphere of the high dose group.
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Target concentrations were: 0.106, 0.319, and 0.956 mg/L (corresponding to 20, 60, and 180 ppm)
- Measured concentrations were: 0.107 ± 0.0061, 0.317 ± 0.0211, 0.958 ± 0.0481 mg/L - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: from study day 69 - study day 80
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- - males: ca. 13 weeks (10 weeks premating, 3 weeks mating and post mating)
- females: ca. 15 weeks (10 weeks premating, during mating and gestation through day 4 after delivery) - Frequency of treatment:
- 6 hours/day, 5 days/week
- Duration of test:
- - males: ca. 13 weeks (10 weeks premating, 3 weeks mating and post mating)
- females: ca. 15 weeks (10 weeks premating, during mating and gestation through day 4 after delivery)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.106 mg/L air (nominal)
- Remarks:
- equals 20 ppm
- Dose / conc.:
- 0.319 mg/L air (nominal)
- Remarks:
- equals 60 ppm
- Dose / conc.:
- 0.956 mg/L air (nominal)
- Remarks:
- equals 180 ppm
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
106 mg/m3 (ca. 20 ppm) : as the expected no observed adverse effect level
319 mg/m3 (ca. 60 ppm) : as the intermediate dose level
956 mg/m3 (ca. 180 ppm): as the dose level where toxic effects were expected
Preflow period of 4 days
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS:
- Time schedule: twice a day (in the morning and in the late afternoon) from Mondays to Fridays and once a day (in the morning) on Saturdays, Sundays and public holidays.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: at least 3 times (before, during and after exposure) on exposure days and once during the preflow period, on the day of neurofunctional test and prior to gross necropsy. During exposure only a group wise examination was possible. The nesting, littering, and lactation behavior of the dams was generally evaluated in the mornings in connection with the daily clinical inspection of the dams. The littering behavior of the dams was also inspected on each workday in the afternoons in addition to the evaluations in the mornings.
BODY WEIGHT:
- Time schedule for examinations: day -7, on day -4 (start preflow period), on day 0(start exposure period) and then in weekly intervals as well as prior to gross necropsy.
FOOD CONSUMPTION:
- Time schedule: day -7, on day -4 (start preflow period), on day 0 (start of exposure period) and then in weekly intervals.
- It was calculated as mean food consumption in grams per animal and day.
- Food efficiency (group means) was calculated based upon individual values for body weight and food consumption.
HAEMATOLOGY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: leukocytes, erythrocytes, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular, haemoglobin concentration, platelets, differential blood count, prothrombin time
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: Blood was taken from the retroorbital venous plexus in the morning from fasted animals without anaesthesia.
- Animals fasted: Yes
- How many animals: all
- Following parameters were examined: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum-y-glutamyltransferase, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium, bile acids
GROSS PATHOLOGY:
The animals were sacrificed under narcoren® anesthesia by exsanguination from the abdominal aorta and vena cava. The animals were necropsied and assessed by gross pathology. To prevent post mortem autolysis, the animals that died intercurrently were necropsied as soon as possible after death.
ORGAN WEIGHTS:
The following weights parameters from all animals sacrificed were determined: anesthetized animals, liver, kidneys, adrenal glands, testes, epididymides, uterus, thymus, spleen, brain, heart, lungs
HISTOPATHOLOGY:
-The following organs or tissues were fixed in 4% formaldehyde solution: all gross lesions, brain, spinal cord (cervical, thoracic and lumber cord), sciatic nerve, pituitary gland, salivary glands (glandula mandibularis and glandula sublingualis), thyroid glands/parathyroid glands, adrenal glands, uterus, oviducts, vagina, female mammary gland, thymus, lymph nodes (mandibular and mesenteric), spleen, trachea, lungs, heart, aorta, liver, pancreas, kidneys, oesophagus, stomach (forestomach and glandular stomach), duodenum, jejunum ileum, caecum, colon, rectum, urinary bladder, sternum with marrow, bone marrow (femur), skull (with nasal cavities, larynx, pharynx, eyes with optic nerve, femur with knee joint, skin, skeletal muscle, extraorbital lacrimal glands. Ovaries of animals that were killed as scheduled were fixed in Bouin's solution and embedded in paraplast, thereafter. Ovaries of animals that died intercurrently were fixed in 4% formaldehyde solution.
- After the organs were fixed, histotechinical processing and examination was were performed as follows: Nasal cavities (level I- IV), Larynx (level I- III), Trachea (longitudinal, with carina), Lungs (5 lobes) and thyroid glands/parathyroid glands in all animals; all gross lesions in all affected animals; evaluations of all other organs and tissues fixed were only performed in animals of the control and high dose group
NEUROBEHAVIOURAL EXAMINATION:
- Detailed clinical observation (DCO) were performed in all animals prior to the exposure period and thereafter in weekly intervals. The findings were ranked according to the degree of severity, if applicable. The following parameters were examined: abnormal behaviour during handling, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, impairment of gait, lacrimation, palpebral closure, exophthalmus, faeces (appearance/consistency), urine, pupil size
- A functional observational battery (FOB) was carried out on the assigned animals (5 males and 5 females/ test group) on study days 56 and 57 for males and females, respectively. On the days of neurofunctional tests there was no exposure of the concerning animals as well as the other 5 animals of the same test group. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests. During the home cage observations attention was paid to posture, tremor, convulsions, abnormal movements, impairments of gait and other findings. During the open field observations the following parameters were examined: behaviour when removed from cage, fur, skin, salivation, nose discharge, lacrimation, eyes/pupil size, posture, palpebral closure, respiration, tremors, convulsions, abnormal movements, impairment of gait, activity/arousal level, faeces (number of faecal pellets/appearance/consistency) within two minutes, urine (appearance/quantity) within two minutes, number of rearings within 2 minutes and other findings. After the open field test animals were subjected to the following sensorimotor or reflex tests: approach response, touch response, vision (visual placing response), pupillary reflex, pinna reflex, audition (startle response), coordination of movements (righting response), behaviour during “handling”, vocalization, pain perception (tail pinch), grip strength of forelimbs, grip strength of hindlimbs, landing foot-splay test and other finding. All findings were ranked according to the degree of severity, if applicable. The observations were performed at random.
- Motor activity (MA) was measured on the same day and with the same animals as FOB was performed. The measurement was performed in the dark using the Multi-Varimex-System (Columbus Instruments Int. Corp., Ohio, USA) with 4 infrared beams per cage. During the measurement the animals were kept in Polycarbonate cages with absorbent material. The animals were put into the cages in a randomized order . The measurements started at about 14:00 p.m. The numbers of beam interrupts were counted over 12 intervals, each lasting 5 minutes. Measurement did not commence at the same instant for all cages ; the period of assessment for each animal started when the first beam was interrupted by pushing the cage into the rack (staggered start). Measurements ended exactly 60 minutes thereafter. During the measurements the animals received no food and no water. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: No
- Number of implantations: Yes
- Number of early resorptions: No
- Number of late resorptions: No - Fetal examinations:
- All surviving pups (after sacrifice on day 4 p.p. by means of C02), all stillborn pups and those pups that died before schedule, were examined externally, eviscerated and their organs were assessed macroscopically. All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation.
- Statistics:
- Two-sided Dunnett test for food consumption, body weight and body weight change, number of mating days, duration of gestation, number of pups
delivered per litter.
Pairwise comparison by the Fisher´s exact test for male and female mating index, male and female fertility index, gestation index, females with liveborn pups, females with stillborn pups, females with all stillborn pups, live birth index, pups stillborn, pups died, pups cannibalized, pups sacrificed moribund, viability index, lactation index, number of litters with affected pups at necropsy and urine analysis except vlume, color, turbidity and specific gravity.
Pairwise comparison by the Wilcoxon test for the proportions of affected pups per litter with necropsy observations.
Non-parametric Kruskal-Wallis test (two-sided)/Wilcoxon test for feces, rearing, grip strength forelimbs, grip strength hindlimbs, landing foot-splay test, motor activity for the different time intervals, clinical pathology parameters except differential blood count and organ weights. - Indices:
- - Viability index (%) = number of live pups on day 4 after birth / number of liveborn pups on the day of birth x 100
- Sex ratio (%) – number of live male or female pups on day (0/4) / number of live male and female pups on day (0/4) x 100 - Historical control data:
- not reported
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Unspecific clinical symptoms indicative for some irritation and systemic toxicity in the high dose group (comprising visually increased respiration, salivation, piloerection, eyelid closure, eye discharge, alopecia, aggressiveness, hyperactivity and apathy).
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Two female animals exposed to the high concentration died on study day 88 and 91 (day 18 and 20 of gestation), respectively. Both animals were found pregnant at death.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Test group 3 (0.956 mg/L = 180 ppm):
Retarded body weight development of the females
- mean body weight: - 3.0 % and -8.0 % of the control from study day 9 onward
(statistically significant on study day 51 )
- mean body weight gain: -19.9 % to - 41.8 % of the control from study day 9 onward (statistically significant )
- Decreased mean terminal body weight in females.
Reduced body weight development in the dams during pregnancy and lactation
- Average weight gain 61 % less than the control between days 0-20 of pregnancy
- Mean body weight on day 20 of pregnancy 24% below control
- Body weights persisted being 19-23% below control during lactation days 0-4, though weight gain was about 60% above control in these females after cessation of exposure on gestation day 18. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The food consumption of the high concentration animals was either decreased only marginally and of transient matter, or increased slightly compared to the control.
Slightly to moderately reduced food consumption of dams during pregnancy (about 16% below control) and lactation days 0-4 (about 39% below control) - Food efficiency:
- no effects observed
- Description (incidence and severity):
- The food efficiency of the high concentration animals was, when compared with the control, only reduced transiently at the beginning of the exposure (day 9).
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There are no treatment-related changes in the haematological parameters measured.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Regarding clinical pathology findings, in the high concentration group females, indications of a reduced general state was seen, characterized by significantly decreased serum creatinine, total protein, albumin and globulin levels. No treatment-related effects were observed in the clinical pathology parameters of the animals of the low and mid concentration groups.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No treatment related findings were observed in the functional observation battery and motor activity examinations.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Due to the significant decrease of the mean terminal body weight in animals (females 9,4 %) of the high dose group, some mean relative organ weights were increased. No morphologic alterations were noted in those organs.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Two female animals of the high dose group died prematurely, revealing non-specific organ changes (atrophy) in the lymphoid tissues of spleen and thymus (both animals) or prefinal erosion/ulcer in the mucosa of the glandular stomach (one animal). Although these findings rather reflect the consequence of a longer story of illness than a treatment-related effect and although none of the findings in thymus, spleen and/or glandular stomach were recorded in the animals killed at scheduled dates.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Hyperplasia of the respiratory epithelium in the nasal cavity at level I in male (incidence) and in female rats (graded severity, only) Hyperplasia of the respiratory epithelium in the nasal cavity at level III in one male rat.
Maternal developmental toxicity
- Dead fetuses:
- effects observed, treatment-related
- Description (incidence and severity):
- In high dose group lower live birth index (80% vs 100% in the control). Lower gestation index (67% vs 100% in the control), 4 out of 6 surviving dams with
liveborn pups, 2 dams with only stillborn pups - Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Insufficient maternal care in 3 females of the high dose group with subsequent complete litter loss until day 3 post delivery
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- histopathology: non-neoplastic
- mortality
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: Lower pup body weights on day 1 p.p. (28% below control). In addition, average pup body weights and body weight gain significantly below control (42% on day 4 p.p. and 67% for days 1-4 p.p., respectively)
- Reduction in number of live offspring:
- effects observed, treatment-related
- Description (incidence and severity):
- In high dose group: lower live birth index (80% vs 100% in the control ). Lower gestation index (67% vs . 100% in the control), 4 out of 6 surviving dams with
liveborn pups, 2 dams with only stillborn pups - Changes in postnatal survival:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: markedly lower viability index (20% vs 97% in the control). Insufficient maternal care in 3 females of the high dose group with subsequent complete litter loss until day 3 post delivery.
- External malformations:
- no effects observed
- Description (incidence and severity):
- At pup necropsy, no malformations were found at any dose level.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- At pup necropsy, no malformations were found at any dose level.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- At pup necropsy, no malformations were found at any dose level.
- Details on embryotoxic / teratogenic effects:
- Details on embryotoxic / teratogenic effects:
At the highest dose level (0.956 mg/L) the pre- and postnatal development of the offspring was substantially impaired. At test concentrations where no maternal toxicity was observed, no embryotoxic,
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.319 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- fetal/pup body weight changes
- changes in postnatal survival
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 0.956 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Any other information on results incl. tables
Dose group (mg/L) 0 0.106 0.319 0.956
maternal body weight
change gd 0 - 20 (g) 91.6 91.5 90.2 35.7**
maternal body weight
lactation day 0 - 4 (g) 10 10 9 6
maternal mortality during
gestation (%) 0 0 0 20
duration of gestation (days) 21.8 21.9 21.9 21.8
gestation index (%) 100 100 100 67
pups delivered 11.0 9.7 10.4 8.3
live birth index (%) 100 100 100 80**
Stillborn (%) 0 0 0 20**
pups died (%) 0.9 0 1.1 36**
pups cannibalized (%) 1.8 1.0 0 28**
pups viability index 97 99 99 20**
pups weight day 1 (g) 6.0 6.2 6.2 4.3**
pups weight day 4 (g) 8.9 9.0 9.2 5.2**
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)